Regorafenib in Patients with Antiangiogenic-Naïve and Chemotherapy-Refractory Advanced Colorectal Cancer: Results from a Phase IIb Trial.

Autor: Riechelmann RP; Department of Radiology and Oncology, Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil rachel.riechelmann@accamargo.org.br.; Department of Clinical Oncology, AC Camargo Cancer Center, São Paulo, Brazil., Leite LS; Department of Radiology and Oncology, Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil., Bariani GM; Department of Radiology and Oncology, Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil., Glasberg J; Department of Radiology and Oncology, Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil., Rivelli TG; Department of Radiology and Oncology, Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil., da Fonseca LG; Department of Radiology and Oncology, Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil., Nebuloni DR; Department of Radiology and Oncology, Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil., Braghiroli MI; Department of Radiology and Oncology, Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil., Queiroz MA; Department of Radiology and Oncology, Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil.; Division of Nuclear Medicine and Molecular Imaging, University of São Paulo, São Paulo, Brazil., Isejima AM; Medical Affairs Study Support, SBU Oncology, Bayer S.A., São Paulo, Brazil., Kappeler C; Clinical Statistics, Global Clinical Oncology, Bayer AG, Berlin, Germany., Kikuchi L; Medical and Data Management, SBU Oncology, Bayer S.A., São Paulo, Brazil., Hoff PM; Department of Radiology and Oncology, Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil.

Publikováno v: The oncologist [Oncologist] 2019 Sep; Vol. 24 (9), pp. 1180-1187. Date of Electronic Publication: 2019 Jun 07.